PRESENTATION · Dec 2024 · PDF

ADH1 - ENDO 2024 Characteristics of Adults with ADH1 enrolled in CLARIFY

PRESENTATION · Dec 2024 · PDF

BBP-418 - MDA 2024 - FORTIFY Phase 3 Trial Design

PRESENTATION · Dec 2024 · PDF

Acoramidis - HFSA 2024 - ATTRibute-CM Post Hoc Recurrent Event Analyses

PRESENTATION · Dec 2024 · PDF

Encaleret - ADH1 - ACMG 2024 Genetic Testing

PRESENTATION · Dec 2024 · PDF

Acoramidis - ESC 2024 - Increase in Serum TTR Levels Observed With Acoramidis Treatment in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights From ATTRibute-CM and Its Open-Label Extension

PRESENTATION · Dec 2024 · PDF

Acoramidis - ISA 2024 - Early increase in serum transthyretin level is an independent predictor of improved survival in ATTR cardiomyopathy

PRESENTATION · Dec 2024 · PDF

Acoramidis - ISA 2024 - Acoramidis treatment-related increase in serum TTR is associated with lower cardiovascular mortality in ATTR-CM

PRESENTATION · Dec 2024 · PDF

BBIO - Acoramidis - ISA 2024 - Acoramidis treatment-related increase in serum TTR is associated with a lower risk of cardiovascular hospitalization in ATTR-CM patients

PRESENTATION · Dec 2024 · PDF

BBIO - Acoramidis - ISA 2024 - Acoramidis achieves early reduction in cardiovascular death or hospitalization in transthyretin amyloid cardiomyopathy (ATTR-CM)

PRESENTATION · Dec 2024 · PDF

BBIO - Acoramidis - ISA 2024 - Higher risk of mortality in previously hospitalized patients